Dicerna Ready To Challenge Alnylam’s RNAi Dominance In 2020
Alliances Help Fund Pivotal Studies
Alnylam set for further expansion in ‘gene silencing’ but Dicerna could have best-in-class rival.
You may also be interested in...
The top-line data in the ultra-rare disease are also the first to demonstrate safety and efficacy of an RNAi therapy in patients six years and younger.
Building on data first reported last December, lumasiran appears on pace for approval by the December 2020 action date, but Dicerna still may show its drug is best-in-class.
The two RNAi firms cross-license IP from their PH programs, while also partnering on a rare liver disease candidate. GSK invests $250m in Vir and will help to advance its antibody candidates for COVID-19.